Introduction {#s0005}
============

Hepatic resection combined with chemotherapy is the standard treatment for patients with hepatic colorectal cancer metastases (CRCLM) and can lead to a 5-year survival of 30% to 58% [@bb0005], [@bb0010]. The improved survival compared to chemotherapy alone, where patients rarely survive beyond 5 years, is ascribed to improvements in operative techniques, perioperative management, better imaging, and more effective chemotherapy. Two first-line therapies, 5-fluorouracil-leucovorin-oxaliplatin and 5-fluorouracil-leucovorin-irinotecan, are approved for advanced-stage CRCLM [@bb0015], [@bb0020]. However, substantial heterogeneity remains in outcomes for patients undergoing resection of CRCLM.

As surgeons become increasingly aggressive in resecting CRCLM, frequently accepting patients over 80 years old and with more extensive comorbidities, it becomes increasingly important to use prudent patient selection criteria based on biologic determinants of outcome. Thus, scoring systems have been developed with the goal of stratifying patients considered for liver resection into risk groups. Such prognostic schemes utilize clinicopathologic variables to estimate the risk of recurrence and death after hepatectomy for CRCLM [@bb0025], [@bb0030], [@bb0035], [@bb0040], [@bb0045]. Patients with a low risk of recurrence after hepatectomy may not benefit from neoadjuvant or adjuvant chemotherapy and may avoid the toxicity of perioperative chemotherapy [@bb0050]. However, when the risk of recurrence is high or the chance of complete resection is in question, delayed hepatectomy after a period of neoadjuvant therapy should be considered [@bb0055]. A neoadjuvant treatment course provides time to determine whether additional disease is present, allows assessment of tumor response to chemotherapy, and may facilitate complete tumor resection in patients with extensive hepatic metastases [@bb0060]. The potential benefits of delayed resection should be weighed against the risk of preoperative hepatotoxicity, disease progression, and the higher complication rates associated with hepatectomy after neoadjuvant therapies [@bb0065]. Although no clinical feature should absolutely exclude a patient from potentially curative hepatectomy, nonoperative management should be considered in those with an exceedingly high risk of recurrence and poor performance status.

The Clinical Risk Score (CRS) is a prognostic scheme composed of five preoperative variables: tumor number; largest tumor diameter; lymph node status during resection of the primary tumor; disease-free interval; and serum carcinoembryonic antigen level [@bb0025]. These are factors prognostic for clinical outcome and are generally available in the preoperative evaluation of patients. The CRS ranges from 0 to 5, depending on the number of unfavorable characteristics present. Each variable in the CRS is equally weighted with a single point for each unfavorable characteristic. Ideal candidates for hepatectomy have solitary metastases with a diameter less than 5 cm, serum CEA (carcinoembryonic antigen) \<200 ng/ml, metachronous disease, and negative regional lymph nodes found at resection of the primary tumor (i.e., CRS = 0). However, even the most favorable CRS of 0 is associated with a 5-year actuarial survival rate of only 60%. Thus, patients within the lowest CRS category are still at risk of recurrence and death.

Although the CRS is a validated prognostic system, it remains imperfect [@bb0070]. One investigation of long-term outcomes after hepatectomy found that patients with a CRS of 0-2 had a 10-year actuarial survival rate twice as high as patients with a CRS of 3-5 (21% versus 10%) [@bb0075]. However, no preoperative clinical feature or CRS precluded a curative outcome in that study. One other study that attempted external validation of three prognostic schemes for CRCLM, including the CRS, failed to confirm any predictive utility in a cohort of 662 patients [@bb0080]. Recently, Dupre et al. reported that scoring systems by themselves are of limited value for stratifying patients operated on for recurrent colorectal liver metastases [@bb0085]. We have sought to improve prognostic schemes in order to better guide clinicians in the application of individualized treatment plans and to determine the best therapeutic course for their patients.

The molecular heterogeneity of colorectal cancer leads to large variations in the response of individual patients to therapy [@bb0090]. Microsatellite instability and a small group of molecular markers, including the mutational status of the *BRAF* and *KRAS* genes, are used for treatment decisions and patient stratification. However, groups of patients defined by these molecular markers still differ significantly in their responses to therapy. In recent years, several approaches to further subtype CRC have come into use, and among the most powerful of these is gene expression profiling, which can improve on the limitations of single gene testing. Gene expression profiling has defined subtypes of colorectal cancers that are predictive or prognostic of patient responses to therapies. [@bb0090]

In the present study, we sought to find prognostic markers for CRCLM and to determine if such markers could improve the accuracy of the CRS. We used microarrays to compare the transcriptome in CRCLM versus their primary tumors. From a group of genes with differential expression between CRCLM and their primary tumors, we selected a subgroup of genes with expression levels that associated with survival or time to disease progression. We validated the findings by quantitative PCR of mRNA from additional patients and found one gene, mitogen inducible factor-6 (*MIG-6*), which was predictive of poor survival. Lastly, we tested whether *MIG-6* expression could substratify patients within defined CRS categories. Our results show that molecular subtypes can complement clinical risk stratification to distinguish lower- from higher-risk patients with CRCLM.

Materials and Methods {#s0010}
=====================

Tumor Retrieval and RNA Extraction {#s0015}
----------------------------------

All institutional review board requirements for human studies were met, and informed consent was obtained from all patients. All tissues were obtained at the time of surgery. All tissues were obtained at the time of surgery. Resected or Tru-cut needle biopsied (superficial) liver metastases (0.5-1.0 g) were snap frozen in the operating room within 2 minutes of harvest by transfer to a Dewar flask containing liquid nitrogen, transported to the laboratory, and stored at −80°C. Similarly, samples of resected primary colon or rectal tumors were taken in the operating room under the observation of a pathologist to preserve surgical and pathological margins and then snap frozen.

Matched samples of primary colon tumor (T); normal colon (N); and, in all but 6 cases, metastatic tumors of the liver (M) were obtained from each of 42 patients treated at the University of California at San Francisco Medical Center. Laser capture microdissection was performed on frozen tissue sections to separate normal and cancerous epithelial cells from surrounding stromal elements.

RNA Extraction {#s0020}
--------------

RNA was extracted from tissue lysates using the RNeasy kit (Qiagen, Inc., Valencia, CA) and amplified using an *in vitro* transcription-mediated procedure that maintains relative abundances of mRNAs [@bb0095]. Each sample was separately labeled with Cy3 and Cy5 fluorescent dyes. Prior to labeling, nonhuman RNA transcripts corresponding to control clones on microarrays were spiked into each sample in known amounts. The amounts of the spiked control transcripts were varied between the Cy3- and Cy5-labelings to create known differentials in the levels of some of these genes. Cy3- or Cy5-labeled nucleotides were incorporated during first-strand cDNA synthesis by reverse transcription using SuperScript II (Invitrogen Corp., Carlsbad, CA), primed with (dT)~25~ and random nonamers (Amersham Biosciences Corp., Piscataway, NJ). Following RNase digestion, the labeled probe was purified using the QIAquick PCR purification kit (Qiagen, Inc., Valencia, CA).

cDNA Microarray Assays {#s0025}
----------------------

DNA microarray analysis was performed as described [@bb0100]. mRNA expression was measured using two-color microarrays containing different sets of cDNA clones. The dsDNA clones were produced by PCR using primers complementary to the vector sequences flanking the cDNA inserts. Each slide included approximately 384 human "housekeeping" genes and non-human (e.g. Arabidopsis thaliana, Drosophila melanogaster, plasmid, etc.) clones for quality control. PCR products were assessed for purity and yield by agarose-gel electrophoresis and were sequenced to verify their identities. Clones found to contain Alu repetitive elements were excluded from further analysis. A total of 36,518 clones that passed the quality criteria were assigned to 1 of 17,708 unique transcripts by GenBank accession number, representing 10,671 unique genes by LocusLink ID. Of these, 6501 genes were measured by at least 2 clones, usually with different sequences. After hybridization and washing, slides were scanned with a Generation III scanner (Molecular Dynamics). Relative gene expression was measured between pairs of co-hybridized samples. Depending on what samples were available from each patient, three comparisons of expression levels were made: metastatic tumor vs. primary tumor (M/T), primary tumor vs. normal epithelium (T/N), and metastatic tumor vs. normal epithelium (M/N). In each comparison, the pair of samples was measured twice with reverse labeling to eliminate bias introduced by the fluorescence properties of the different dyes. For 32 of the patients, T/N, M/N and M/T expression were all measured.

Microarray Data Analysis {#s0030}
------------------------

Microarray image analysis was performed using ImaGene software (BioDiscovery, El Segundo, CA). For each spot, the median pixel intensity and standard deviation were determined, as well as the spot area, signal area, and local background intensity. For each cDNA clone, the results from four spots (two duplicates per slide, Cy3 and Cy5 labeled) were averaged, and a standard deviation was calculated. A clone was detected if its signal was at least 5 standard deviations above background. A ratio of expression between the two samples and its uncertainty were calculated from the intensities. Each array was normalized such that the median ratio observed among the clones measuring genes spiked into the Cy3 and Cy5 samples in equal amounts was one. A global normalization was then applied such that the median ratio observed across all of the cDNA spots on all of the arrays for each sample was 1. For each ratio, a significance call was assigned: undetected (in both the numerator and denominator), on (detected in the numerator only), off (detected in the denominator only), up or down (significantly over-expressed in the numerator or denominator, respectively), or equal (detected, but ratio not significantly different from one). To be called significantly up- (down-) regulated, a gene's expression must not only be greater (less) than the cut, but it had to be greater (less) than 1 with at least 95% certainty based on the uncertainty in the log ratio.

For the 32 patients that had T/N, M/N, and M/T expression measurements, consistency was required between the results of the three measurements for each spot, such that 4/5 \< (T/N)\*(M/T)/(M/N) \< 5/4, i.e., the three ratios should cancel to give a value of 1 within 25%. A list of genes that were differently expressed by more than 1.5-fold between the metastatic and primary tumors of these patients was generated. The number of ratios deemed sufficiently well measured to use (detected; consistent between T/N, M/N, and M/T measurements) varied for different spots. At least 10 good measurements were required for each spot to be considered. A total of 22,344 of 36,518 spots, assigned to 8027 of the 10,671 unique genes on the arrays, passed this criterion. Maximum likelihood estimates of the upper and lower 99% confidence limits on the prevalence in the parent population were calculated for each spot on the basis of the number of ratios exceeding the cut out of the number of good ratios. Spots judged to be up- or downregulated in 20% of the parent population with 99% certainty were included in the list. Thus, if only 10 good ratios were measured for a particular spot, 7 would have to make the cut (70%); if there were 32 good ratios, 14 would suffice (43%). When more than one spot assigned to a particular gene met these criteria, their average expression ratio in each patient was calculated, weighted by the inverse uncertainty squared for each ratio.

RT and qRT-PCR {#s0035}
--------------

cDNAs were synthesized from 2 μg total RNA using a SuperScript III first-strand synthesis kit. One microliter of the first cDNA synthesis mix was dispensed in triplicate and mixed with Taqman Universal PCR Mastermix and Taqman Gene Expression Assays in an end-volume of 10 μl into optical 384-well plates for Taqman RT-PCR. PCR primers for *MIG-6* \[Hs00219060_m1\], fibronectin 1 (HS00415006_m1), tissue inhibitor of metalloproteinase-1 \[Hs00171558_m1\], serine proteinase inhibitor member 2 \[Hs00299953_m1\], lumican \[Hs00158940_m1\], basic helix-loop-helix domain containing class B2 \[Hs00186419\], transmembrane 4 superfamily member-1 \[Hs00371997\], and the TaqMan probe were obtained from Applied Biosystems. Actin-B \[Hs99999903_m1\] was chosen as an endogenous normalization control. The Applied Biosystems ABI Prism 7900 was used for qRT-PCR. Samples were incubated at 95°C for 15 minutes, followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. In nontemplate control replicates of each gene, no false positives were detected, and all the assays were done in triplicate. Quantitative RT-PCR triplicate runs were repeated on a separate day to confirm reproducibility.

Statistical Analysis {#s0040}
--------------------

We screened the transcriptome for associations between candidate gene expression and outcomes using linear regression analysis. Categorical variables were compared by Chi-square tests. Overall survival was estimated using the Kaplan-Meier method. Survival curve estimates were compared by the log-rank test. Cox proportional-hazards regression was performed on independent variables that were added sequentially in a stepwise fashion such that they were entered if *P* \< .05 and removed if *P* \> .10. Statistical calculations were done with MedCalc Version 7.0.1.0 software (Mariakerke, Belgium). Two-sided *P* values \< .05 were considered statistically significant. Where applicable, the cutoff point for stratifying gene expression groups was determined using the Maxstat statistical package in R (The R Foundation for Statistical Computing, Version 2.0.0, Vienna, Austria. ISBN 3-900051-00-3, URL: [http://cran.r-project.org/](http://www.R-project.org){#ir0005}).

Results {#s0045}
=======

Candidate Genes Selected from the Screening Microarray {#s0050}
------------------------------------------------------

Using a cDNA-based microarray that included 35,518 spots representing 10,671 unique genes, we screened the transcriptome for genes that were differentially expressed in unresected metastases of colorectal cancer relative to their primary tumors in 42 patients. The characteristics of these patients were: median age 59 years (range 31-82); 61% male, 29% female; primary tumor site 43% right colon, 33% left colon, 2% right and left colon, 22% rectum; primary node status 15% positive, 85% negative; time to progression 91% \</= 12 months (synchronous) and 9% \>12 months (metachronous); the median number of hepatic metastases was 3 with a range of 1-11; and the average CEA was 141.

In the screen, 22,344 spots representing 8,027 unique genes met criteria for analysis. From the 10,671 genes in the microarray, 144 demonstrated differential expression between primary colon tumors and matched hepatic metastases. Differential expression was defined as at least 1.5-fold difference in at least 20% of matched primary and metastatic samples. Transcripts showing a tendency for increased expression in the metastases relative to primary tumors are in [Table 1](#t0005){ref-type="table"}, while those exhibiting decreased expression are in [Table 2](#t0010){ref-type="table"}. Hierarchical clustering applying the Pearson correlation for the distance metric and complete linkage identified six distinct spot clusters, which are shown in the heat map of differentially expressed genes ([Figure 1](#f0005){ref-type="fig"}).Table 1Sixty-Eight Genes with Increased mRNA Expression in Hepatic Metastases Relative to Primary Colon Tumors from the Same PatientTable 1Locus IDSymbolGeneSpots*N*\>1.5×\>2×\>4×\>10×ONCLUST8991SELENBP1selenium binding protein 113056.7%43.3%23.3%6.7%0.0%3163732CITED4Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 412653.8%38.5%23.1%7.7%0.0%34060LUMlumican43262.5%43.8%15.6%0.0%0.0%55266PI3protease inhibitor 3, skin-derived (SKALP)12653.8%50.0%11.5%3.8%0.0%327290SPINK4serine protease inhibitor, Kazal type 412152.4%28.6%28.6%9.5%0.0%327248XTP3TPBXTP3-transactivated protein B12650.0%34.6%19.2%7.7%0.0%39518GDF15growth differentiation factor 1523151.6%38.7%16.1%3.2%0.0%6374354FLJ25621FLJ25621 protein12352.2%34.8%17.4%4.3%0.0%32192FBLN1fibulin 121553.3%46.7%6.7%0.0%0.0%511167FSTL1follistatin-like 123161.3%41.9%3.2%0.0%0.0%54313MMP2matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)22665.4%34.6%3.8%0.0%0.0%52049EPHB3EphB312748.1%33.3%18.5%3.7%0.0%6800CALD1caldesmon 112850.0%39.3%10.7%3.6%0.0%557535KIAA1324maba112751.9%33.3%7.4%3.7%3.7%34535MTND1NADH dehydrogenase 123063.3%36.7%0.0%0.0%0.0%41634DCNdecorin63253.1%28.1%15.6%0.0%0.0%526073POLDIP2polymerase (DNA-directed), delta interacting protein 212751.9%29.6%14.8%0.0%0.0%326047CNTNAP2contactin associated protein-like 212152.4%28.6%4.8%0.0%9.5%41513CTSKcathepsin K (pycnodysostosis)11553.3%33.3%6.7%0.0%0.0%5131177FAM3Dfamily with sequence similarity 3, member D12948.3%24.1%13.8%6.9%0.0%35786PTPRAprotein tyrosine phosphatase, receptor type, A12958.6%34.5%0.0%0.0%0.0%45327PLATplasminogen activator, tissue22860.7%28.6%0.0%0.0%0.0%510406WFDC2WAP four-disulfide core domain 212552.0%24.0%12.0%0.0%0.0%31278COL1A2collagen, type I, alpha 223243.8%31.3%9.4%3.1%0.0%5132160FLJ32332likely ortholog of mouse protein phosphatase 2C eta13148.4%32.3%6.5%0.0%0.0%44536MTND2NADH dehydrogenase 223154.8%29.0%3.2%0.0%0.0%47433VIPR1vasoactive intestinal peptide receptor 112157.1%28.6%0.0%0.0%0.0%34091MADH6MAD, mothers against decapentaplegic homolog 6 (Drosophila)12860.7%25.0%0.0%0.0%0.0%41277COL1A1collagen, type I, alpha 112050.0%30.0%5.0%0.0%0.0%51504CTRB1chymotrypsinogen B113053.3%26.7%3.3%0.0%0.0%46741SSBSjogren syndrome antigen B (autoantigen La)12755.6%25.9%0.0%0.0%0.0%427122DKK3dickkopf homolog 3 (Xenopus laevis)12050.0%25.0%5.0%0.0%0.0%523469PHF3PHD finger protein 313060.0%20.0%0.0%0.0%0.0%45908RAP1BRAP1B, member of RAS oncogene family13053.3%26.7%0.0%0.0%0.0%45295PIK3R1phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)12552.0%24.0%4.0%0.0%0.0%43297HSF1heat shock transcription factor 113056.7%23.3%0.0%0.0%0.0%42A2Malpha-2-macroglobulin13046.7%26.7%6.7%0.0%0.0%581558LOC81558C/EBP-induced protein12951.7%24.1%3.4%0.0%0.0%45801PTPRRprotein tyrosine phosphatase, receptor type, R12944.8%31.0%3.4%0.0%0.0%32487FRZBfrizzled-related protein11855.6%16.7%5.6%0.0%0.0%36348CCL3chemokine (C-C motif) ligand 312751.9%22.2%3.7%0.0%0.0%42006ELNelastin (supravalvular aortic stenosis, Williams-Beuren syndrome)12748.1%29.6%0.0%0.0%0.0%484859MGC4126hypothetical protein MGC412623145.2%25.8%6.5%0.0%0.0%54513MTCO2cytochrome c oxidase II33151.6%22.6%3.2%0.0%0.0%4146880MGC40489hypothetical protein MGC4048913046.7%26.7%3.3%0.0%0.0%483483PLVAPplasmalemma vesicle associated protein12548.0%28.0%0.0%0.0%0.0%56678SPARCsecreted protein, acidic, cysteine-rich (osteonectin)12944.8%24.1%6.9%0.0%0.0%5132241LOC132241hypothetical protein LOC13224112951.7%20.7%3.4%0.0%0.0%467122NrarpNotch-regulated ankyrin repeat protein12842.9%28.6%3.6%0.0%0.0%3398ARHGDIGRho GDP dissociation inhibitor (GDI) gamma12744.4%18.5%11.1%0.0%0.0%451599LISCH7liver-specific bHLH-Zip transcription factor13050.0%23.3%0.0%0.0%0.0%481788SNARKlikely ortholog of rat SNF1/AMP-activated protein kinase12951.7%20.7%0.0%0.0%0.0%457605PITPNM2phosphatidylinositol transfer protein, membrane-associated 212951.7%20.7%0.0%0.0%0.0%451332SPTBN5spectrin, beta, non-erythrocytic 512548.0%20.0%4.0%0.0%0.0%44541MTND6NADH dehydrogenase 663243.8%25.0%3.1%0.0%0.0%456940DUSP22dual specificity phosphatase 2212748.1%22.2%0.0%0.0%0.0%52580GAKcyclin G associated kinase12751.9%18.5%0.0%0.0%0.0%423432GPR161G protein-coupled receptor 16112948.3%20.7%0.0%0.0%0.0%4583BBS2Bardet-Biedl syndrome 212948.3%20.7%0.0%0.0%0.0%42045EPHA7EphA712846.4%21.4%0.0%0.0%0.0%43189HNRPH3heterogeneous nuclear ribonucleoprotein H3 (2H9)13148.4%19.4%0.0%0.0%0.0%41158CKMcreatine kinase, muscle13046.7%20.0%0.0%0.0%0.0%49775DDX48DEAD (Asp-Glu-Ala-Asp) box polypeptide 4812445.8%20.8%0.0%0.0%0.0%410551AGR2anterior gradient 2 homolog (Xenopus laevis)22941.4%24.1%0.0%0.0%0.0%31999ELF3E74-like factor 3 (ets domain transcription factor, epithelial-specific )13043.3%20.0%0.0%0.0%0.0%327336HTATSF1HIV TAT specific factor 112944.8%17.2%0.0%0.0%0.0%47125TNNC2troponin C2, fast12842.9%14.3%0.0%0.0%0.0%43040HBA2hemoglobin, alpha 212748.1%3.7%0.0%0.0%0.0%5[^2]Table 2Seventy-Six Genes with Decreased mRNA Expression in Hepatic Metastases Relative to Primary Colon Tumors from the Same PatientTable 2Locus IDSymbolGeneSpots*N*\>1.5×\>2×\>4×\>10×OFFCLUST12SERPINA3serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 322564.0%60.0%48.0%24.0%0.0%151761ATP8A2ATPase, aminophospholipid transporter-like, Class I, type 8A, member 211560.0%53.3%40.0%26.7%0.0%151129ANGPTL4angiopoietin-like 411866.7%61.1%22.2%5.6%0.0%2348APOEapolipoprotein E23259.4%50.0%31.3%6.3%0.0%55004ORM1orosomucoid 111957.9%42.1%26.3%15.8%0.0%13240HPhaptoglobin72951.7%41.4%27.6%17.2%0.0%16347CCL2chemokine (C-C motif) ligand 222171.4%42.9%14.3%4.8%0.0%527295PDLIM3PDZ and LIM domain 311464.3%50.0%7.1%0.0%7.1%5213ALBalbumin11450.0%35.7%21.4%14.3%0.0%27076TIMP1tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)33167.7%41.9%6.5%0.0%0.0%62335FN1fibronectin 143256.3%40.6%18.8%0.0%0.0%6710SERPING1serine (or cysteine) proteinase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)12650.0%34.6%26.9%3.8%0.0%58553BHLHB2basic helix-loop-helix domain containing, class B, 212657.7%53.8%0.0%0.0%0.0%63303HSPA1Aheat shock 70kDa protein 1A43148.4%35.5%22.6%3.2%0.0%36373CXCL11chemokine (C-X-C motif) ligand 1111163.6%18.2%9.1%0.0%18.2%556937TMEPAItransmembrane, prostate androgen induced RNA12548.0%40.0%16.0%4.0%0.0%66035RNASE1ribonuclease, RNase A family, 1 (pancreatic)12955.2%31.0%13.8%6.9%0.0%32316FLNAfilamin A, alpha (actin binding protein 280)23151.6%41.9%12.9%0.0%0.0%5768CA9carbonic anhydrase IX11844.4%33.3%16.7%0.0%11.1%62885GRB2growth factor receptor-bound protein 212157.1%33.3%14.3%0.0%0.0%57564ZNF16zinc finger protein 16 (KOX 9)12751.9%44.4%7.4%0.0%0.0%64070TACSTD2tumor-associated calcium signal transducer 212850.0%28.6%17.9%7.1%0.0%67052TGM2transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)12857.1%32.1%14.3%0.0%0.0%64071TM4SF1transmembrane 4 superfamily member 112951.7%41.4%6.9%3.4%0.0%410397NDRG1N-myc downstream regulated gene 113056.7%40.0%6.7%0.0%0.0%22207FCER1GFc fragment of IgE, high affinity I, receptor for; gamma polypeptide12161.9%33.3%4.8%0.0%0.0%51152CKBcreatine kinase, brain33250.0%31.3%12.5%6.3%0.0%31514CTSLcathepsin L43154.8%29.0%9.7%3.2%0.0%5652BMP4bone morphogenetic protein 412450.0%37.5%8.3%0.0%0.0%6633BGNbiglycan12458.3%37.5%0.0%0.0%0.0%13936LCP1lymphocyte cytosolic protein 1 (L-plastin)12347.8%26.1%13.0%8.7%0.0%52878GPX3glutathione peroxidase 3 (plasma)11855.6%33.3%5.6%0.0%0.0%17422VEGFvascular endothelial growth factor23053.3%33.3%6.7%0.0%0.0%24256MGPmatrix Gla protein13046.7%36.7%10.0%0.0%0.0%1374AREGamphiregulin (schwannoma-derived growth factor)12944.8%27.6%13.8%6.9%0.0%47701ZNF142zinc finger protein 142 (clone pHZ-49)12846.4%32.1%14.3%0.0%0.0%351366DD5progestin induced protein12744.4%37.0%11.1%0.0%0.0%610457GPNMBglycoprotein (transmembrane) nmb12650.0%30.8%11.5%0.0%0.0%522822PHLDA1pleckstrin homology-like domain, family A, member 112450.0%33.3%8.3%0.0%0.0%610123ARL7ADP-ribosylation factor-like 733246.9%31.3%6.3%6.3%0.0%64316MMP7matrix metalloproteinase 7 (matrilysin, uterine)63246.9%31.3%9.4%3.1%0.0%63576IL8interleukin 812147.6%33.3%4.8%4.8%0.0%65163PDK1pyruvate dehydrogenase kinase, isoenzyme 112958.6%31.0%0.0%0.0%0.0%21649DDIT3DNA-damage-inducible transcript 312846.4%35.7%7.1%0.0%0.0%27033TFF3trefoil factor 3 (intestinal)12744.4%22.2%14.8%3.7%3.7%34493MT1Emetallothionein 1E (functional)12646.2%30.8%11.5%0.0%0.0%37481WNT11wingless-type MMTV integration site family, member 1111752.9%23.5%5.9%0.0%5.9%410381TUBB4tubulin, beta, 411560.0%26.7%0.0%0.0%0.0%15270SERPINE2serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 212846.4%32.1%3.6%3.6%0.0%69590AKAP12A kinase (PRKA) anchor protein (gravin) 1212050.0%25.0%5.0%5.0%0.0%254206*MIG-6*mitogen-inducible gene 613145.2%35.5%3.2%0.0%0.0%211067C10orf10chromosome 10 open reading frame 1012462.5%20.8%0.0%0.0%0.0%62159F10coagulation factor X11850.0%33.3%0.0%0.0%0.0%457561ARRDC3arrestin domain containing 332759.3%22.2%0.0%0.0%0.0%64495MT1Gmetallothionein 1G12744.4%22.2%11.1%3.7%0.0%310628TXNIPthioredoxin interacting protein53246.9%31.3%3.1%0.0%0.0%33939LDHAlactate dehydrogenase A23253.1%25.0%3.1%0.0%0.0%66890TAP1transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)12445.8%20.8%8.3%4.2%0.0%31942EFNA1ephrin-A112846.4%32.1%0.0%0.0%0.0%4136ADORA2Badenosine A2b receptor12250.0%27.3%0.0%0.0%0.0%311145HRASLS3HRAS-like suppressor 312646.2%30.8%0.0%0.0%0.0%684951CTENC-terminal tensin-like12152.4%19.0%4.8%0.0%0.0%690637LOC90637hypothetical protein LOC9063712944.8%27.6%3.4%0.0%0.0%27045TGFBItransforming growth factor, beta-induced, 68kDa12450.0%25.0%0.0%0.0%0.0%65230PGK1phosphoglycerate kinase 113246.9%25.0%3.1%0.0%0.0%664065PERPPERP, TP53 apoptosis effector12846.4%17.9%3.6%3.6%0.0%69531BAG3BCL2-associated athanogene 312842.9%25.0%3.6%0.0%0.0%223023KIAA0779KIAA0779 protein12147.6%23.8%0.0%0.0%0.0%3567B2Mbeta-2-microglobulin12846.4%17.9%0.0%0.0%0.0%32317FLNBfilamin B, beta (actin binding protein 278)12842.9%14.3%7.1%0.0%0.0%3665BNIP3LBCL2/adenovirus E1B 19kDa interacting protein 3-like23046.7%16.7%0.0%0.0%0.0%27431VIMvimentin12842.9%14.3%3.6%0.0%0.0%591452ACBD5acyl-Coenzyme A binding domain containing 512744.4%14.8%0.0%0.0%0.0%41508CTSBcathepsin B13148.4%9.7%0.0%0.0%0.0%655818JMJD1jumonji domain containing 112842.9%14.3%0.0%0.0%0.0%65763PTMSparathymosin13141.9%12.9%0.0%0.0%0.0%3[^3]Figure 1Expression of genes that show significant up- or downregulation in metastatic tumors of the liver relative to primary colon tumors from the same patient in 20% or more of the patient population with 99% certainty based on a sampling of 32 patients. Upregulation is indicated by shades of red, downregulation is indicated by shades of green, black indicates no change, and gray indicates ratios that failed to pass detection or consistency criteria. [Tables 1](#t0005){ref-type="table"} and [2](#t0010){ref-type="table"} indicate which cluster each of the genes belongs to.Figure 1

We found 68 genes that were consistently up-regulated and 76 that were down-regulated in CRCLM relative to matched primary tumors. From this group of 144 differentially expressed genes, 7 were selected for validation based on the association between mRNA level (using values obtained from the microarray) and clinical outcome ([Table 3](#t0015){ref-type="table"}): lumican, a proteoglycan of the extracellular matrix reported to be overexpressed in colorectal breast, neuroendocrine, and other cancers [@bb0105]; tissue inhibitor of metalloproteinase 1 (TIMP1), an inhibitor of matrix metalloproteinases and modulator of other diverse processes in cancer cells [@bb0110]; basic helix-loop-helix domain containing B2 (BHLHB2), a transcription factor that is induced by hypoxia within tumors [@bb0115]; fibronectin, an abundant extracellular matrix protein that contributes to altered stromal remodeling during tumorigenesis [@bb0120]; TM4SF1 (transmembrane 4 superfamily member 1), a tumor-associated antigen that regulates cancer cell motility and invasion [@bb0125]; serpine2, an extracellular serine protease that is overexpressed in pancreatic, colon, and stomach cancers that may facilitate invasive processes [@bb0130]; and *MIG-6*, a putative tumor suppressor that negatively regulates the ErbB family of receptor tyrosine kinases [@bb0135], [@bb0140].Table 3Seven Candidate Genes Were Selected on the Basis of Differential Expression Between Colorectal Liver Metastases and Their Corresponding Primary Tumor and an Association Between mRNA Level (as Determined by the Microarray Analysis) and Clinical Outcome (*P*\<.05)Table 3Candidate GeneNameRelative Expression in CRCLMClinical VariableLUMLumicanHigherOSTIMP1Tissue inhibitor of\
metalloproteinase 1LowerTTP\
TSBHLHB2Basic helix-loop-helix domain containing, class B, 2LowerOSFN1FibronectinLowerTTPTM4SF1Transmembrane 4\
superfamily member 1LowerOS*MIG-6*Mitogen-inducible gene 6LowerTTPSER2Serpine2LowerOS\
TS[^4]

Association of Candidate Genes in CRC Metastases with Clinical Outcome {#s0055}
----------------------------------------------------------------------

To determine whether the expression of the candidate genes identified above as correlating with clinical outcome for unresectable patients with colorectal metastases confined to the liver also applied to patients undergoing potentially curative hepatectomy for CRCLM, we performed qRT-PCR of the 7 candidate genes on CRCLM from 56 additional patients. qRT-PCR allowed us to more accurately quantify the levels of each transcript than obtaining such information from an array and therefore allowed more accurate substratification of patients into *MIG-6*--high and *MIG-6*--low groups. Since we often did not have matching primary tumors for these patients, mRNA levels of the metastasis and normal tissue were compared. The baseline clinical variables and their association with overall survival of the group of 56 patients who underwent potentially curative hepatectomy are in [Table 4](#t0020){ref-type="table"}. The median follow-up time of the surviving patients in this group was 97 months after hepatectomy (range 55-107 months).Table 4Results of Univariate Association of Clinicopathologic Variables with Overall SurvivalTable 4Variable*n*Median Survival (Months)Hazard Ratio95% CI*P* ValueAge26680.630.33-1.18.15 \<60 ≥603036Sex Female18370.880.46-1.70.71 Male3832Date of hepatectomy After January 1, 200019291.280.65-2.71.44 Before January 1, 20003740Primary tumor site Colon47361.030.46-2.34.94 Rectum951Disease-free interval Metachronous23540.610.33-1.17.14 Synchronous3333Hepatic lobe involvement Unilobar40361.320.66-2.58.44 Bilobar1636Primary tumor node status N014430.840.42-1.69.63 N14136Preoperative CEA \<200 ng/ml39331.370.52-3.44.55 ≥200 ng/ml665Diameter of largest met \<5.0 cm28580.500.25-0.91.03 ≥5.0 cm2830Number of metastases Solitary27540.570.30-1.05.07 Multiple2929Hepatectomy EBL \<1000 ml30361.160.62-2.19.64 ≥1000 ml2533Hepatectomy margin \<1.0 cm27401.110.59-2.08.74 ≥1.0 cm2931[^5]

To determine if expression of any of the seven genes was associated with survival after hepatectomy, we dichotomized patients into high- and low-expression groups according to the median relative mRNA level. In this analysis, *MIG-6* was the only gene whose expression was predictive of survival ([Table 5](#t0025){ref-type="table"}). Patients in the lower 50th percentile of *MIG-6* expression had a median survival that was over twice as long as that of patients in the upper 50th percentile (*P* = .01, [Table 5](#t0025){ref-type="table"}). Using Maxstat software to optimize the cutoff value for high and low *MIG-6* expression, a statistically significant difference in overall survival was found by Kaplan-Meier analysis (log-rank *P* = .0024, [Figure 2](#f0010){ref-type="fig"}). This approach also showed that none of the candidate genes, including *MIG-6*, was predictive of liver disease--free survival (LDFS) ([Table 5](#t0025){ref-type="table"}).Table 5Univariate Analysis of Candidate GenesTable 5Candidate Gene Expression*n*Median Survival (mos)Hazard Ratio (95% CI)*P* Value SurvivalMedian LDFS\
(mos)Hazard Ratio (95% CI)*P* Value LDFSLUM Low28500.64.19510.55.10 High2732(0.30-1.28)20(0.24-1.14)TIMP1 Low28570.60.14510.51.07 High2831(0.29-1.19)20(0.23-1.06)BHLHB2 Low28570.59.13NR0.55.11 High2831(0.28-1.17)27(0.26-1.16)FN1 Low28570.63.18460.80.54 High2831(0.30-1.26)27(0.37-1.69)TM4SF1 Low28420.90.77460.94.86 High2831(0.44-1.83)27(0.44-1.99)Mig-6 Low28670.42[**.01**]{.ul}NR0.55.10 High2829(0.18-0.80)20(0.24-1.12)SER2 Low28420.79.50460.76.47 High2731(0.38-1.61)20(0.35-1.62)[^6]Figure 2Kaplan-Meier survival estimates of survival in patients after resection stratified by *MIG-6* expression. MaxStat software was used to optimize the cutoff value for high and low *MIG-6* expression. A statistically significant difference in overall survival was found by this analysis (log-rank *P* = .0024)Figure 2

High- and Low-CRS Patients Further Stratified by MIG-6 Gene Expression {#s0060}
----------------------------------------------------------------------

Because *MIG-6* was the only gene whose expression predicted survival, we were interested in whether patients with a high or low CRS could be further stratified by *MIG-6* expression. This led us to perform qRT-PCR of *MIG-6* mRNA on 25 additional patients with CRCLM (total *n* = 81 patients). To determine if the CRS predicted survival after hepatectomy in this cohort, we generated Kaplan-Meier survival estimates of low CRS (0-2) and high CRS (3-5). Although the median survival of the low CRS group was not reached, the median survival of the high-CRS group was 25 months. The Kaplan-Meier survival estimates for the low-CRS group were higher than those for the high-CRS group (log-rank *P* = .005, [Figure 3](#f0015){ref-type="fig"}). Within the low-CRS group (*n* = 40), stratifying by median *MIG-6* expression resulted in low-- (*n* = 20) and high-- (*n* = 20) *MIG-6* expression subgroups ([Figure 4](#f0020){ref-type="fig"}*A*). Median survival was 33 months for patients in the subgroup with low CRS and high *MIG-6* but was not reached in the subgroup with low CRS and low *MIG-6*. When patients in the low-CRS group were substratified by the median *MIG-6* level, statistically distinct survival curves by log-rank testing (*P* = .03) resulted.Figure 3Patient stratification for overall survival by CRS. Kaplan-Meier survival estimates comparing low-CRS (0-2) vs. high-CRS (3--5) groups. The median overall survival was 25 months in the high-CRS group, but it was not reached in the low-CRS group (*P* = .005). Fourteen patients did not have preoperative CEA levels and were excluded from the analysis. Numbers below the figure are life tables designating how many patients are represented in the survival curves.Figure 3Figure 4*MIG-6* can substratify patients beyond the CRS. Patients divided into low-CRS (0-2) and high-CRS (3-5) groups were further stratified by median *MIG-6* expression. **(**A**)** Within the low-CRS group, patients were separated into two groups: those in the upper 50th percentile of *MIG-6* expression and those in the lower 50th percentile. The median overall survival was 33 months in the upper--*MIG-6* subgroup and was not reached in the lower--*MIG-6* group (*P* = .03). **(**B**)** Similarly, within the high-CRS group, patients were separated into two groups: those in the upper 50th percentile of *MIG-6* expression and those in the lower 50th percentile. The median overall survival in the upper-- and lower--*MIG-6* subgroups was 18 and 33 months, respectively (*P* = .04). Numbers below the figure are life tables designating how many patients are represented in the survival curves.Figure 4

When patients in the high-CRS group (*n* = 41) were stratified by median *MIG-6* expression, the median survival was almost twice as long in the low--*MIG-6* subgroup (*n* = 21) as it was in the high--*MIG-6* subgroup (*n* =20) ([Figure 4](#f0020){ref-type="fig"}*B*). As with the low-CRS group, patients with a high CRS could be effectively substratified by median *MIG-6* expression, resulting in statistically distinct survival curves by log-rank testing (*P* = .04).

Discussion {#s0065}
==========

We used gene expression profiling to identify differentially expressed genes in CRCLM relative to matched primary tumors. Among the genes identified, *MIG-6* (also called gene-33, RALT, or ERRFI1) encodes an adaptor protein that interacts with and inhibits the activities of members of the ErbB receptor family and other receptor tyrosine kinases [@bb0145], [@bb0150]. The human *MIG-6* gene is on chromosome 1p36, a locus associated with many cancers [@bb0155], and *MIG-6* is proposed to be a tumor suppressor [@bb0140], [@bb0160]. Consistent with this, *MIG-6* expression is reduced in human breast, skin, pancreatic, and ovarian cancers, and diminished *MIG-6* expression in patients with breast cancer correlates with poor survival [@bb0165], [@bb0170]. Furthermore, germline disruption of the murine *MIG-6* gene leads to cancers of the lung, gallbladder, bile duct, skin, and gastrointestinal tract [@bb0145], [@bb0160]. Identification of *MIG-6* as a gene that has low expression in CRCLM relative to matched primary cancers may suggest that *MIG-6* can act as a suppressor of metastasis.

We found that elevated *MIG-6* mRNA expression was associated with decreased survival after hepatectomy of CRCLM. This observation should be considered in concert with results showing that *MIG-6* has diverse functions in both physiology and pathology which, depending on context, can promote survival or cell death.

*MIG-6* transcription is induced by diverse stimuli including growth factors [@bb0175], [@bb0180], hormones [@bb0185], cytokines [@bb0145], [@bb0190], and hypoxia [@bb0195]. *MIG-6* is a feedback inhibitor of all members of the ErbB receptor family [@bb0145], [@bb0150], with the EGFR being best investigated. Activation of the EGFR increases *MIG-6* transcription in a RAS-ERK--dependent fashion [@bb0200], [@bb0205], leading to accumulation of the *MIG-6* protein within 60-90 minutes. In turn, *MIG-6* binds the tyrosine kinase domain of the activated EGFR, inactivates the receptor tyrosine kinase, and thereby attenuates EGFR action. Thus, *MIG-6* ^−/−^ mice display epidermal hyperplasia and have an increased susceptibility to skin carcinogenesis, which is caused by unabated EGFR signaling [@bb0145]. During lung development and vascularization, the absence of *MIG-6* leads to hyperplasia of several tissues, as well as to enhanced apoptosis of endothelial cells and diminished expression of angiogenic factors [@bb0210]. Considered together, the observations summarized above show that that *MIG-6* may coordinate life and death decision making to facilitate tissue homeostasis [@bb0135], [@bb0140].

It has been commonly assumed that *MIG-6* functions solely as a tumor suppressor and that EGFR acts in an oncogenic manner. However, several studies have established the ability of EGFR to induce apoptosis in breast cancer cells [@bb0215], [@bb0220], [@bb0225], [@bb0230], [@bb0235], while others have established the ability of *MIG-6* to protect human breast cancer cells from apoptosis [@bb0210], [@bb0240]. A strong basis exists for believing that unbalanced expression of *MIG-6* relative to the EGFR activates internalized EGFR, where it may initiate apoptosis [@bb0215], [@bb0220], [@bb0230], [@bb0235], [@bb0245]. Recent studies show that phosphorylation of *MIG-6* may negatively affect its interaction with the EGFR as well as its capacity to induce trafficking of the EGFR [@bb0150], [@bb0250], [@bb0255]. Since the activity of *MIG-6* on EGFR is dependent on its phosphorylation status, localization, and protein levels, it may be necessary to interrogate these attributes of *MIG-6* in patients to know its true prognostic significance.

Petroda et al. [@bb0260] recently showed that the identification of molecular subtypes of colorectal metastases across individual patients can complement clinical risk stratification to distinguish low-, intermediate-, and high-risk patients with distinct 10-year survivals. The present study builds on this approach by showing that CRCLM patients could be stratified within their respective CRS group by relative *MIG-6* expression to improve prognostic accuracy for patients. Our observations should encourage evaluation of patient outcomes when *MIG-6* expression and *MIG-6* expression relative to EGFR localization and abundance are considered in a larger, prospective study.

This study had several limitations. The patients whose tumor specimens were used in the screening array had unresected CRCLM, whereas patients in the validation group underwent hepatectomy. Ideally, screening and validation groups have identical clinical features and undergo identical treatment. Furthermore, the samples utilized were not randomly selected but rather represented patients who had tissue available for research. We defined high and low *MIG-6* expression by retrospectively selecting the most significant cutoff by log-rank testing. We also used the median expression of *MIG-6* to dichotomize patients as a relatively unbiased means of stratifying beyond the CRS. We acknowledge that reaching conclusions using cut points from maximally selected statistics and multiple hypothesis testing requires further validation. The ultimate confirmation of the association between *MIG-6* expression and survival after hepatectomy requires larger and perhaps prospective studies.

Despite these limitations, many of which are inevitable in research with human tumor specimens, we believe that our central conclusions are of interest: high *MIG-6* expression is a negative prognostic feature in CRCLM; furthermore, determination of *MIG-6* expression can augment the accuracy of prognostic schemes that rely on clinicopathologic data.

Author Contributions {#s0080}
====================

D. B. D., D. T. R., and R. S. W. planned the studies. D. T. R., R. J. A., R. S. W., and D. B. D. wrote the manuscript. K. T., E. K. B., E. K. N., M. H. L., and R. J. A. prepared the figures and tables and contributed to data analysis.

Funding: This study was approved and supported by the National Comprehensive Cancer Network and by the Littlefield Family Foundation. The funding agencies were not involved in the design of the study and collection, analysis and interpretation of data, and writing the manuscript.

Declarations of Interest: None.

[^1]: These authors contributed equally to this work.

[^2]: Each gene is identified by its LocusLink ID, symbol, and name. The "Spots" column indicates the number of spots (cDNA clones) used to measure each gene's expression. The "*N*" column shows the maximum number of patient samples where a particular gene was measured; this number was used in calculating the average percent prevalence across patients. The average prevalence, for cuts of 1.5-, 2-, 4-, and 10- fold increased M/T expression, or cases where the gene was only detected in the metastatic tumor sample ("ON"), is shown as a percentage of the patients where the gene was measured. The "CLUST" column indicates which of the clusters shown in [Figure 1](#f0005){ref-type="fig"} each gene belongs to. The genes are ordered by the sum of the prevalence values, in decreasing order.

[^3]: The columns are the same as in [Table 1](#t0005){ref-type="table"}, except that the prevalence columns indicate percentage of patients exhibiting downregulation and the "OFF" column indicates the percentage of patients where expression was detected in the primary tumor but not the metastasis.

[^4]: *OS*, overall survival; *TTP*, time to progression of liver metastases.

[^5]: Preoperative CEA level was not obtained in 13 patients. Primary tumor nodal status was unknown in two patients. *CEA*, carcinoembryonic antigen; *met*, metastasis.

[^6]: Quantitative RT-PCR was performed on colorectal liver metastases from 56 additional patients that underwent hepatectomy. Patients above and below the median expression level were compared by log-rank testing.
